Midsize biotech companies pressed the White House and HHS to drop pending CMS pricing models, arguing the rules could hinder business operations. The companies’ outreach followed concerns that proposed Medicare pricing structures would make planning and investment difficult for development-stage manufacturers. The appeal comes as reimbursement uncertainty remains a persistent headwind for specialty drug makers, particularly those reliant on predictable coverage and pricing assumptions. Industry stakeholders also continue monitoring federal moves that affect drug affordability, patient access, and the economics of specialty medicines. While CMS and the White House have not indicated changes, the meetings signal that pricing methodology proposals are now directly triggering lobbying and stakeholder coordination.